Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
APPLE Pilot Trial
NCT03100123Phase 1Terminated
- Sponsor
- Ottawa Hospital Research Institute
- Start
- Nov 2017
- Primary completion
- Oct 2019
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of low molecular weight heparin calcium in antiphospholipid syndrome (APS) and recurrent pregnancy loss (RPL) (2 arms), sponsored by Ottawa Hospital Research Institute. Primary endpoint: Mean Recruitment Rate Per Center Per Month at 24 months. Started Nov 2017; status: terminated.
02
Drugs
low molecular weight heparin calcium
03
Conditions
antiphospholipid syndrome (APS)recurrent pregnancy loss (RPL)
Beyond the preview
Go deeper on NCT03100123.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03100123.